Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal Melanoma
Source: OncLive, February 2024
Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.
Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the clinical significance of updated data from the phase 3 IMCgp100-202 trial (NCT03070392) of tebentafusp-tebn (Kimmtrak) in previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, as well as next steps planned for this research.
The randomized IMCgp100-202 study assessed tebentafusp in patients with metastatic uveal melanoma vs standard of care pembrolizumab (Keytruda), ipilimumab (Yervoy) or dacarbazine. Updated findings from a 3-year analysis showed that tebentafusp produced a median overall survival (OS) of (95% CI, 19.0-24.3) vs 16.9 months (95% CI, 12.9-19.5) with the agents in the comparator arm (n = 126; HR, 0.68; 95% CI, 0.54-0.87), demonstrating a significant survival benefit. This benefit was consistently observed across patients with poor prognostic factors. Tebentafusp also maintained superior 1– and 2-year progression-free survival (PFS) rates compared with the control arm.